DS-8201a, a new HER2-targeting antibody-drug conjugate incorporating a novel DNA topoisomerase I inhibitor, overcomes HER2-positive gastric cancer T-DM1 resistance-Reference-Cited by-同舟云学术

DS-8201a, a new HER2-targeting antibody-drug conjugate incorporating a novel DNA topoisomerase I inhibitor, overcomes HER2-positive gastric cancer T-DM1 resistance

Published:2017-07-12 Issue:8 Volume:141 Page:1682-1689
ISSN:0020-7136
Container-title:International Journal of Cancer
language:en
Short-container-title:Int. J. Cancer

Author:

Takegawa Naoki¹,Nonagase Yoshikane¹,Yonesaka Kimio¹^ORCID,Sakai Kazuko²,Maenishi Osamu³,Ogitani Yusuke⁴,Tamura Takao¹,Nishio Kazuto²,Nakagawa Kazuhiko¹,Tsurutani Junji¹^ORCID

Affiliation:

1. Department of Medical Oncology; Kindai University Faculty of Medicine; Osaka-Sayamashi Osaka Japan

2. Department of Genome Biology; Kindai University Faculty of Medicine; Osaka-Sayamashi Osaka Japan

3. Department of Pathology; Kindai University Faculty of Medicine; Osaka-Sayamashi Osaka Japan

4. Biologics & Immuno-Oncology Laboratories; Daiichi Sankyo Co., Ltd; Shinagawa-ku Tokyo Japan

Funder

Daiichi Sankyo Co., Ltd

Publisher

Wiley

Subject

Cancer Research,Oncology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/ijc.30870/fullpdf

Reference32 articles.

1. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer;Slamon;Science,1989

2. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene;Slamon;Science,1987

3. Assessment of a HER2 scoring system for gastric cancer: results from a validation study;Hofmann;Histopathology,2008

4. HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target;Gravalos;Ann Oncol,2008

5. Overexpression of Grb2/HER2 signaling in Chinese gastric cancer: their relationship with clinicopathological parameters and prognostic significance;Yu;J Cancer Res Clin Oncol,2009

Cited by 130 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Clinical strategies with antibody–drug conjugates as potential modifications for virotherapy;Drug Discovery Today;2024-09

2. Resistance to Anti-HER2 Therapies in Gastrointestinal Malignancies;Cancers;2024-08-15

3. HER-2 positive gastric cancer: Current targeted treatments;International Journal of Biological Macromolecules;2024-08

4. Antibody–drug conjugates in cancer therapy: mechanisms and clinical studies;MedComm;2024-07-28

5. Exploring treatment options in cancer: tumor treatment strategies;Signal Transduction and Targeted Therapy;2024-07-17